ライフサイエンスコーパス: metalloproteinase inhibitor

1 lly inhibited by TIMP-3, a matrix-associated metalloproteinase inhibitor.

2 t that CT-PCPE may constitute a new class of metalloproteinase inhibitor.

3 titis, even after pretreatment with a matrix metalloproteinase inhibitor.

4 mphocytes, even in the presence of KB8301, a metalloproteinase inhibitor.

5 umor necrosis factor alpha-converting enzyme metalloproteinase inhibitor.

6 ble by the addition of hydroxamic acid-based metalloproteinase inhibitors.

7 h proenzyme processing and interactions with metalloproteinase inhibitors.

8 was reduced significantly by treatment with metalloproteinase inhibitors.

9 IV is not inhibited by thiol-, carboxyl-, or metalloproteinase inhibitors.

10 g is inhibited at low temperature but not by metalloproteinase inhibitors.

11 ptor (EPCR) release that is not inhibited by metalloproteinase inhibitors.

12 ed bone resorption in the presence of matrix metalloproteinase inhibitors.

13 ase-2 and matrix metalloproteinase-9, tissue metalloproteinase inhibitor 1, and C-terminal propeptide

14 Matrix metalloproteinase 9, metalloproteinase inhibitor 1, monocyte chemoattractant

15 smembrane NRG-1beta and was inhibited by the metalloproteinase inhibitor 1,10-phenanthroline.

16 The metalloproteinase inhibitor 1-10-phenanthroline inhibite

17 Synthetic metalloproteinase inhibitor (1 mM) or citrate (12 mM) pr

18 uding apparent crosslinked species of tissue metalloproteinase inhibitor 3 and vitronectin, and carbo

19 Tissue metalloproteinase inhibitor 3, clusterin, vitronectin, a

20 R-181b expression, along with a reduction of metalloproteinase inhibitor 3.

21 of EGF receptor activation, using heparin, a metalloproteinase inhibitor and neutralizing antibodies

22 ar shedding of E-cadherin was abrogated by a metalloproteinase inhibitor and through the introduction

23 Their appearance was inhibited by specific metalloproteinase inhibitors and also by lactobionate, t

24 TIMP-3 is a member of a family of metalloproteinase inhibitors and blocks A disintegrin an

25 data support the notion of combining matrix metalloproteinase inhibitors and cytotoxic agents to tre

26 hin 2 min, and this release was inhibited by metalloproteinase inhibitors and the TACE inhibitor TAPI

27 Shedding was inhibited by cycloheximide, a metalloproteinase inhibitor, and protein kinase C inhibi

28 onoclonal antibody 225 IgG, by two different metalloproteinase inhibitors, and by neutralizing antibo

29 ment can be inhibited with the use of matrix metalloproteinase inhibitors, and suggests a mechanistic

30 studies of a series of proline-based matrix metalloproteinase inhibitors are described.

31 or Con A-induced hepatitis, and that matrix metalloproteinase inhibitors are ineffective in preventi

32 These results uncover metalloproteinase inhibitors as critical stromal factors

33 Sensitivity to known matrix metalloproteinase inhibitors as well as to the endogenou

34 The addition of a matrix metalloproteinase inhibitor attenuated NKp46 downregulat

35 increased collagenase activity, because the metalloproteinase inhibitor batimastat had no effect.

36 EGFR, and pretreatment with a broad spectrum metalloproteinase inhibitor batimastat reduced NT-induce

37 ivation was blocked by pretreatment with the metalloproteinase inhibitor Batimastat/GM6001, the EGFR

38 the specific HB-EGF inhibitor CRM197 or the metalloproteinase inhibitors batimastat or phenanthrolin

39 Du cells was inhibited by treatment with the metalloproteinase inhibitor, batimastat.

40 atment with phenanthroline and the synthetic metalloproteinase inhibitor BB-3103 reduced the levels o

41 Mice treated with the broad-spectrum metalloproteinase inhibitor BB-94 (50 mg/kg, i.p.) showe

42 binant TIMP-1, but not TIMP-2 or a synthetic metalloproteinase inhibitor (BB-94), confers resistance

43 ate 13-acetate and can be inhibited with two metalloproteinase inhibitors, BB-94 (Batimastat) and GM6

44 nhibition of migration by the broad spectrum metalloproteinase inhibitor BB3103, demonstrated that me

45 AM17) catalytic activity, and broad spectrum metalloproteinase inhibitors block EGFR transactivation

46 appearance of soluble AR, and two different metalloproteinase inhibitors blocked AR release.

47 Synthetic metalloproteinase inhibitor, but not citrate, generated

48 0 mandibular explants with a hydroxamic acid metalloproteinase inhibitor, but not with inhibitors of

49 igel by tumor cells was largely abolished by metalloproteinase inhibitors, but not by inhibitors of o

50 It is likely that adjuvant use of matrix metalloproteinase inhibitors can significantly enhance t

51 iogenic compounds, including TNP-470, matrix metalloproteinase inhibitors, carboxyamidotriazole, and

52 lls with an EGFR-neutralizing antibody, or a metalloproteinase inhibitor, decreased the acrolein-indu

53 Treatment with metalloproteinase inhibitors did not alter the qualitati

54 e combined use of chemotherapeutic drugs and metalloproteinase inhibitors enhances NK cell-mediated r

55 However, administration of a matrix metalloproteinase inhibitor exacerbates liver injury, in

56 In vitro, the matrix metalloproteinase inhibitor FN-439 promoted survival of

57 administration of the broad-spectrum matrix metalloproteinase inhibitor Galardin for 3 days in combi

58 n both isotypes by the broad-spectrum matrix metalloproteinase inhibitor, galardin (GM 6001).

59 Here we report that a matrix metalloproteinase inhibitor, GM-6001, improves survival

60 The metalloproteinase inhibitor, GM-6001, prevented the indu

61 Inhibition with a broad-spectrum metalloproteinase inhibitor GM6001 (100 mg/kg) ameliorat

62 Interestingly, the matrix metalloproteinase inhibitor GM6001 (ilomastat), which is

63 ndrocytes was blocked in the presence of the metalloproteinase inhibitor GM6001 and the gamma-secreta

64 f EGFR ligands, as the broad-spectrum matrix metalloproteinase inhibitor GM6001 could inhibit this ef

65 ectodomain shedding of Dsg2 with the matrix metalloproteinase inhibitor GM6001 resulted in accumulat

66 timulated cleavage is inhibited by the broad metalloproteinase inhibitor GM6001, a fact that suggests

67 growth suppression properties of the matrix metalloproteinase inhibitor GM6001.

68 carbonyl-Val-Leu-leucinal but insensitive to metalloproteinase inhibitor GM6001.

69 HB-EGF neutralizing antibody, or the matrix metalloproteinase inhibitor GM6001.

70 thylprednisolone and a broad-spectrum matrix metalloproteinase inhibitor (GM6001) did not develop emp

71 GFR) inhibitor (tyrphostin AG1478), a matrix metalloproteinase inhibitor (GM6001), or a heparin-bindi

72 A broad-spectrum metalloproteinase inhibitor, GM6001/Ilomastat, acted syn

73 gamma delta T cells, and in the presence of metalloproteinase-inhibitors >70% of gamma delta T cells

74 Recently, a class of matrix metalloproteinase inhibitors has been identified that ca

75 Specific metalloproteinase inhibitors have been used to block tum

76 Interferons, matrix metalloproteinase inhibitors, imatinib and gefitinib hav

77 rons was sufficient to confer sensitivity to metalloproteinase inhibitors in neurite outgrowth assays

78 Metalloproteinase inhibitors inactivated amylin-degradin

79 We report that metalloproteinase inhibitors, including EDTA, EGTA, and

80 Preventing the cleavage of FasL with a metalloproteinase inhibitor increased H. pylori-mediated

81 Treatment of microglia with a metalloproteinase inhibitor inhibited LRP1 shedding and

82 ression analysis showed that TIMP3, a tissue metalloproteinase inhibitor, is a common target of miR-2

83 General matrix metalloproteinase inhibitors limited the resorption of b

84 asion, the combination of TMZ and the matrix metalloproteinase inhibitor marimastat (MRM) in patients

85 e accelerated with the broad-spectrum matrix metalloproteinase inhibitor Marimastat, which may result

86 struction syndrome, establishing that matrix metalloproteinase inhibitors may be a therapeutically vi

87 The hypothesis that matrix metalloproteinase inhibitors may be useful for experimen

88 Synthetic metalloproteinase inhibitors may modify the ratio of tra

89 Matrix metalloproteinase inhibitors (MMPIs) reduce blood-brain

90 mercapto-4-arylsulfonamidopyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synt

91 -converting enzyme, can be blocked by matrix metalloproteinase inhibitors (MMPIs).

92 or a novel series of piperazine-based matrix metalloproteinase inhibitors (MMPIs).

93 is using technetium-99m-labeled broad matrix metalloproteinase inhibitor (MPI) and to determine the e

94 Technetium-99m-labeled matrix metalloproteinase inhibitor (MPI) was used for the nonin

95 mor models were so compelling that synthetic metalloproteinase inhibitors (MPIs) were rapidly develop

96 Metalloproteinase inhibitors often feature hydroxamate m

97 lucidate the effect of doxycycline, a matrix metalloproteinase inhibitor, on cardiac injury and funct

98 Incubation with a synthetic metalloproteinase inhibitor or adenoviral overexpression

99 rogation of the MMP9 catalytic activity by a metalloproteinase inhibitor or blocking antibody decreas

100 Clearance was attenuated by metalloproteinase inhibitors or antibodies to disintegri

101 nhibition of TMEFF2 shedding using synthetic metalloproteinase inhibitors or small interfering RNA ta

102 reatment of mature cortical neurons with pan-metalloproteinase inhibitors or with tissue inhibitors o

103 scular endothelial growth factor) and matrix metalloproteinase inhibitor (plasminogen activator inhib

104 Preincubation with a metalloproteinase inhibitor prevented L-selectin loss.

105 metalloproteinases with a broad-based matrix metalloproteinase inhibitor prevented LV dilation in the

106 ctional filopodial extension, whereas matrix metalloproteinase inhibitors prevented sprout extension

107 Administration of matrix metalloproteinase inhibitors prevented the signs and his

108 Doxycycline, a matrix metalloproteinase inhibitor, prevented matrix metallopro

109 of accelerated exiting, administration of a metalloproteinase inhibitor prevents macrophage efflux b

110 using TIMP or several families of synthetic metalloproteinase inhibitors reduced outflow rates.

111 Addition of a specific metalloproteinase inhibitor resulted in the abrogation o

112 ideo microscopy shows that the presence of a metalloproteinase inhibitor results in a doubling of the

113 emonstrated that treating tumors with matrix metalloproteinase inhibitors results in tumor reduction

114 helial migration assays and a zinc-dependent metalloproteinase inhibitor, Ro 31-9790 (N-2-((2s)-[(hyd

115 of mitogenic signaling by PDGF-B in a matrix metalloproteinase inhibitor-sensitive fashion.

116 red ARPE-19 migration toward HGF in a matrix metalloproteinase inhibitor-sensitive manner.

117 A topical synthetic metalloproteinase inhibitor (SIMP) has been reported to

118 Metalloproteinase inhibitor studies show that constituti

119 us, localized induction of endogenous matrix metalloproteinase inhibitors, such as TIMP-4, holds prom

120 le HBEGF in cultures exposed to low O(2) and metalloproteinase inhibitor suggests that the effects of

121 this hypothesis, cotreatment of EC with the metalloproteinase inhibitor Tapi (TNF-alpha proteinase i

122 ons at this S2 cleavage site, the use of the metalloproteinase inhibitor TAPI-2, as well as small int

123 , the release of sVLDLR-N was inhibited by a metalloproteinase inhibitor, TAPI-1, while it was promot

124 Interferons, matrix metalloproteinase inhibitors, thalidomide, bevacizumab,

125 Actinonin and matlystatins are potent metalloproteinase inhibitors that comprise rare N-hydrox

126 the search for a number of synthetic matrix metalloproteinase inhibitors that could serve as potenti

127 egulated the expression of TIMP3, a secreted metalloproteinase inhibitor, that inhibited MMP14 to blo

128 and border zones at 3 months, and the matrix metalloproteinase inhibitor TIMP-4 increased dramaticall

129 ation by augmenting levels of the endogenous metalloproteinase inhibitor, tissue inhibitor of metallo

130 suggests that elevated levels of the matrix metalloproteinase inhibitor, tissue inhibitor of metallo

131 The ability of several specific matrix metalloproteinase inhibitors to reduce outflow facility

132 When BB-94, a matrix metalloproteinase inhibitor, was added to the culture me

133 A metalloproteinase inhibitor, WAY171318, reduced CCh-indu

134 metic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied.

135 osis factor-alpha stimulation was blocked by metalloproteinase inhibitors, whereas serine protease in

136 ease from cells was blocked by addition of a metalloproteinase inhibitor which concomitantly caused t

137 at, agents initially characterized as matrix metalloproteinase inhibitors which are in early stages o

138 nced by the pretreatment of tumor cells with metalloproteinase inhibitors, which increased expression

139 By reverse zymography, we have observed a metalloproteinase inhibitor with an apparent molecular w

140 Results reveal legume protein MMPIs as novel metalloproteinase inhibitors with possible pharmacologic

141 ocal delivery of Ilomastat, a general matrix metalloproteinase inhibitor, with the use of ethylene-vi